Latest Abbott Stories

Canada has one of the highest prevalence of IBD in the world with one in 160 Canadians living with IBD and 9,200 new cases diagnosed each year* MONTREAL, May 15, 2012 /CNW/ - As global attention turns towards inflammatory bowel disease (IBD) with the upcoming World IBD Day on May 19(th), a group of patients who live with this chronic condition are celebrating World IBD Day early with a public event taking place on May 15(th) at the ByWard Market in Ottawa. The group, called Gut...

CAMBRIDGE, Mass., May 15, 2012 /PRNewswire/ -- IntelligentMDx (IMDx) announced today that it has obtained CE-marking for a new automated, high-throughput, qualitative in vitro diagnostic test designed for the rapid detection of Group B Streptococcus (GBS) for use in screening pregnant women and those in labor who may be infected with the pathogen. GBS is responsible for life-threatening bacterial infections in newborns, including sepsis, meningitis, and pneumonia. The IMDx(TM) GBS for...

PARIS, May 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the XIENCE PRIME(TM) and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. This is the shortest duration of DAPT for any major drug eluting stent (DES) in Europe. Patients are prescribed DAPT, a combination of aspirin and...

LAS VEGAS, May 10, 2012 /PRNewswire/ -- An innovative program that screens women for heart disease during a visit to the gynecologist has found that nearly one in eight women has three or more cardiac risk factors but many don't know it, according to a study presented today at the SCAI 2012 Scientific Sessions. The ob/gyn screening program, launched in October 2010, is a result of a collaboration between SCAI's Women in Innovations ("WIN") and Abbott's Women's Heart Health...

Device is the First Blood Glucose System in North America to Offer Mealtime Insulin Calculator TORONTO, May 9, 2012 /PRNewswire/ - Abbott today announced that its new FreeStyle InsuLinx Blood Glucose Monitoring System(1) is now available in diabetes centres and select pharmacies across Canada. It is the first blood glucose monitoring device in North America that offers a mealtime insulin calculator for calculating suggested insulin doses. The FreeStyle InsuLinx System is...

WASHINGTON, May 7, 2012 /PRNewswire/ -- In what may be the largest payment ever enforced involving off-label misuse of a single drug, law firm Grant & Eisenhofer, working with the U.S. Justice Department and several state Attorneys General, has reached a $1.6 billion settlement with Abbott Laboratories over its illegal marketing of antiepileptic medication Depakote to children and geriatric patients. The settlement was reached between Abbott (NYSE: ABT) and the Justice...

ABBOTT PARK, Ill., May 7, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) has reached a settlement with U.S. federal and 49 state authorities, plus the District of Columbia, to resolve all outstanding issues regarding a previously disclosed investigation of past sales and marketing practices relating to its neurologic medication Depakote. The settlement results from a four-year-old investigation into past sales activities that began in 1998 involving this product. Abbott cooperated fully with...

ABBOTT PARK, Ill. and AARHUS, Denmark, May 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) and Action Pharma A/S, a privately owned company, today announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma. AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in adjacent indications. AP214 is a hormone analogue that targets both systemic...

MUMBAI and BANGALORE, India, May 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT), one of India's largest health care companies, today announced plans to establish its first nutrition research and development center in the country in collaboration with Syngene, India's leading contract research organization. The Abbott Nutrition R&D Center in India will focus on the development of science-based, affordable nutrition products for the country and enable the expansion of Abbott's nutrition...

ABBOTT PARK, Ill., May 2, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will participate in the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8, 2012. Thomas C. Freyman, executive vice president, finance and chief financial officer and John M. Leonard, M.D., senior vice president, pharmaceuticals, research and development, will participate in a 35-minute question and answer session regarding the company beginning at 9 a.m. Central time. A live audio webcast of the...